SOAGY (Sartorius AG) Current Deferred Revenue : $0 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Sartorius AG Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sartorius AG's current deferred revenue for the quarter that ended in Sep. 2024 was $0 Mil.

Sartorius AG Current Deferred Revenue Historical Data

The historical data trend for Sartorius AG's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Current Deferred Revenue Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

Sartorius AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Sartorius AG Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SOAGY) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

SSSGY:USA SUVPF:USA SARTF:USA 1SRT:Italy 1SRT3:Italy SRT3d:UK 0NIR:UK 0NIQ:UK SRT3:Germany SRT3:Bulgaria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.